Compare
The details that actually shape the buying decision.
Evidence, risk, regulatory flags, cost, and vendor coverage — side by side, without affiliate spin.
01· Subject
Angiotensin 1-7
Protective renin-angiotensin-system peptide studied for vascular, anti-inflammatory, and anti-fibrotic effects.
Tier Blow risk
02· Subject
Elamipretide
Clinical-stage mitochondria-targeting peptide binding cardiolipin. Not a typical consumer RUO product.
Tier Bmedium risk
01 · At a glance
| Decision factor | Angiotensin 1-7 | Elamipretide | Thymosin Alpha-1 |
|---|---|---|---|
| Primary fit | longevity & anti-aging and immune support comparisons | longevity & anti-aging research where you want a clear starting point | longevity & anti-aging and immune support comparisons |
| Evidence | Tier B | Tier B | Tier B |
| Risk | low | medium | medium |
| Experience level | advanced | advanced | intermediate |
| Budget tier | premium | premium | mid |
| Administration route | intravenous, subcutaneous | subcutaneous, intravenous | subcutaneous |
02 · Use case & timing
| Decision factor | Angiotensin 1-7 | Elamipretide | Thymosin Alpha-1 |
|---|---|---|---|
| Goal fit | Longevity & Anti-Aging, Immune Support | Longevity & Anti-Aging | Longevity & Anti-Aging, Immune Support |
| What users compare it for | Potential endothelial, anti-inflammatory, and anti-fibrotic benefits in vascular and pulmonary research settings. | Mitochondrial function improvement in disease contexts (clinical-stage). | Immune modulation; clinical literature broader than most RUO peptides. |
| Onset timeline | Hemodynamic effects can appear quickly during infusion; structural outcomes are studied over longer periods. | Trial endpoints measured over months in disease-specific contexts. | Immune biomarkers and clinical outcomes over weeks to months. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. |
03 · Safety & restrictions
| Decision factor | Angiotensin 1-7 | Elamipretide | Thymosin Alpha-1 |
|---|---|---|---|
| Adverse effects | Main practical risk is hypotension or reflex tachycardia, especially in combination with other RAAS-active therapies. | Injection site reactions common in some trial summaries; long-term safety depends on indication. | Generally tolerable in clinical contexts; clinician oversight required. |
| Contraindications | Avoid in hypotension, volume depletion, and use caution with ACE inhibitors or ARBs. | Clinical trial context; not consumer self-administration. | Potential interactions with immunotherapies/vaccines. |
| Interaction notes | Likely additive blood-pressure lowering with ACE inhibitors, ARBs, and other vasodilating strategies. | Unknown in consumer context. | Potential interactions with immunotherapies/vaccines; do not provide combination advice. |
| Regulatory status | Investigational | Investigational | Investigational |
| FDA flag | No current flag noted | FDA status unclear | FDA status unclear |
| WADA status | Not listed | Not listed | Not listed |
04 · Age & monitoring
| Decision factor | Angiotensin 1-7 | Elamipretide | Thymosin Alpha-1 |
|---|---|---|---|
| Supported age ranges | No age guidance yet | No age guidance yet | 35-44, 45-54, 55-64, 65+ |
| Life-stage note | Not yet documented | Not yet documented | Age fit improves later in life because immune-support logic becomes more relevant as immunosenescence rises. |
| Monitoring burden | Not specified | Not specified | medium |
| Follow-up cadence | Not yet documented | Not yet documented | Periodic reassessment every few months, especially if health context is complex. |
05 · Cost & sourcing
| Decision factor | Angiotensin 1-7 | Elamipretide | Thymosin Alpha-1 |
|---|---|---|---|
| Typical cycle cost | No reliable estimate yet | €371.52 | $79.98 |
| Estimated monthly cost | No reliable estimate yet | €371.52 | $53.32 |
| Cost confidence | No estimate | High confidence | High confidence |
06 · Before you buy
| Decision factor | Angiotensin 1-7 | Elamipretide | Thymosin Alpha-1 |
|---|---|---|---|
| Tracked vendor listings | 0 listings | 1 listing | 1 listing |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | Tracked product pages are available, which makes it easier to review the listing before you click out. | Tracked product pages are available, which makes it easier to review the listing before you click out. |
| Stack-friendly? | Usually stack-friendly | Better as a standalone decision | Usually stack-friendly |
Still deciding
Get a plan tailored to you.
Side-by-side narrows the field. The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.